Biomarker Changes in Response to Tofacitinib Treatment in Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis
Arthritis Care & Research · 2024
DOI: 10.1002/acr.25417 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Arthritis Care & Research, 2024. Verfasst von Ekemini A Ogbu und 17 weiteren Autor:innen. Beteiligte Einrichtung: Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Ohio, and Johns Hopkins University, Baltimore, Maryland. Hauptthemen laut MEDLINE: Arthritis, Juvenile, Piperidines, Biomarkers, Pyrimidines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAMS NIH HHS, Ralph & Marian Falk Medical Trust Catalyst Award, Pfizer.
Abstract (Originalsprache)
Objective
We examine levels of candidate blood‐based biomarkers (CBBs) in patients with juvenile idiopathic arthritis (JIA) treated with tofacitinib.
Methods
Patients with JIA who participated in clinical trial NCT02592434 received tofacitinib from baseline to week 18. Serial serum samples were assayed for CBBs (S100A8/9, S100A12, interleukin‐18 [IL‐18], serum amyloid A, resistin, vascular endothelial growth factor, angiopoietin‐1, angiopoietin‐2, matrix metalloproteinase 8 [MMP8], MMP2, tissue inhibitor of metalloproteinases 1, leptin, chemokine [C‐X‐C motif] ligand 9, soluble IL‐2 receptor, intercellular adhesion molecule 1, soluble tumor necrosis factor receptor, IL‐6, IL‐23, monocyte chemotactic protein 1, chemokine [C‐C motif] ligand 18 [CCL18], and CCL20). Association of CBBs with JIA response to treatment from baseline to week 18 were assessed.
Results
This study included 166 patients with polyarticular‐course JIA. Paired serum samples from 143 patients were available at both baseline and week 18. Thirty‐five percent (50 of 143) of patients had a JIA‐American College of Rheumatology 90 (JIA‐ACR90) level improvement, whereas 90, 121, and 137 (63%, 85%, and 96%) achieved JIA‐ACR70, 50, and 30 improvement at week 18. Despite small numerical differences by JIA category, there were no baseline CBB values that independently predicted a decrease in Juvenile Arthritis Disease Activity Score (JADAS‐27) or JIA‐ACR90 response by week 18. Decrease in resistin level (baseline to week 18) was significantly associated with week 18 improvement in JADAS‐27 and JIA‐ACR90 response after adjusting for age, sex, JIA disease duration, and baseline resistin (r 2 0.79, SE 0.070, P < 0.01, and odds ratio [95% confidence interval] 1.134 [1.018–1.264]). HLA‐B27 positivity was significantly associated with not achieving a JIA‐ACR90 response at week 18 ( P = 0.0097).
Conclusion
Among the CBBs included, only resistin was significantly associated with treatment response, and no CBB was identified that forecasts JIA improvement after initiation of tofacitinib. The association of HLA‐B27 positivity with lower response to tofacitinib in JIA is intriguing and merits further study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Ohio, and Johns Hopkins University, Baltimore, Maryland.
- Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Ohio.
- Cincinnati Children's Hospital Medical Center, Ohio, and Assiut University Faculty of Medicine, Assiut, Egypt.
- Rambam Health Care Campus, Haifa, Israel.
- Seattle Children's Hospital and University of Washington School of Medicine.
- Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada.
ORCID-Profile: Ekemini A Ogbu, Hermine I Brunner, Esraa Eloseily, Yonatan Butbul Aviel, Heinrike Schmeling, Heather Tory, Yosef Uziel, Dawn M Wahezi, Stacey E Tarvin, Nicolino Ruperto, Bin Huang, Sherry Thornton
Förderung
- NIAMS NIH HHS
- Ralph & Marian Falk Medical Trust Catalyst Award
- Pfizer
- NIH HHS
- Cincinnati Children's Hospital Medical Center Pediatric Musculoskeletal & Rheumatology Innovation Core center (PORTICO)
- NCATS NIH HHS
- National Institutes of Health
Zitieren
APA
Ogbu, E. A., Brunner, H. I., Eloseily, E., Aviel, Y. B., Nanda, K., Schmeling, H., Tory, H., Uziel, Y., Viola, D. O., Wahezi, D. M., Tarvin, S. E., Sproles, A., Chen, C., Ruperto, N., Huang, B., Grom, A., Thornton, S., & Investigators of the PRINTO and PRCSG Networks (2024). Biomarker Changes in Response to Tofacitinib Treatment in Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis. Arthritis Care & Research. https://doi.org/10.1002/acr.25417
Vancouver
Ogbu EA, Brunner HI, Eloseily E, Aviel YB, Nanda K, Schmeling H, et al. Biomarker Changes in Response to Tofacitinib Treatment in Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis. Arthritis Care & Research. 2024. doi:10.1002/acr.25417
BibTeX
@article{Ogbu2024,
author = {Ogbu, Ekemini A and Brunner, Hermine I and Eloseily, Esraa and Aviel, Yonatan Butbul and Nanda, Kabita and Schmeling, Heinrike and Tory, Heather and Uziel, Yosef and Viola, Diego Oscar and Wahezi, Dawn M and Tarvin, Stacey E and Sproles, Alyssa and Chen, Chen and Ruperto, Nicolino and Huang, Bin and Grom, Alexei and Thornton, Sherry and Investigators of the PRINTO and PRCSG Networks, Investigators of the PRINTO and PRCSG Networks},
title = {Biomarker Changes in Response to Tofacitinib Treatment in Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis},
journal = {Arthritis Care & Research},
year = {2024},
doi = {10.1002/acr.25417}
}
EUVIMED